Search
5-formyltetrahydrofolate cyclo-ligase
go.drugbank.com/bio_entities/BE0001906TargetMycoplasma pneumoniae (strain ATCC 29342 / M129)Catalyzes the irreversible conversion of 5-formyltetrahydrofolate (5-FTHF) to yield 5,10-methenyltetrahydrofolate.
Polypeptides: 5-formyltetrahydrofolate cyclo-ligaseFunction: 5-formyltetrahydrofolate cyclo-ligase activityAdenylate cyclase type 5
go.drugbank.com/bio_entities/BE0003733TargetHumansCatalyzes the formation of the signaling molecule cAMP in response to G protein signaling (PubMed:15385642, PubMed:24700542, PubMed:26206488). Mediates signaling downstream of ADRB1 (PubMed:24700542). Regulates the increase of free cytos...
Polypeptides: Adenylate cyclase type 5Synonyms: Adenylyl cyclase 5, ATP pyrophosphate-lyase 5Ribose-5-phosphate isomerase
go.drugbank.com/bio_entities/BE0004438TargetHumansCatalyzes the reversible conversion of ribose-5-phosphate to ribulose 5-phosphate and participates in the first step of the non-oxidative branch of the pentose phosphate pathway
Polypeptides: Ribose-5-phosphate isomeraseUridine 5'-monophosphate synthase
go.drugbank.com/bio_entities/BE0004473TargetEnzymeHumans-5'-monophosphate decarboxylase (ODC), the terminal enzymatic reaction that decarboxylates OMP to uridine monophosphate (UMP) … Bifunctional enzyme catalyzing the last two steps of de novo pyrimidine biosynthesis, orotate phosphoribosyltransferase (OPRT), which converts orotate to orotidine-5'-monophosphate (OMP), and orotidine
Polypeptides: Uridine 5'-monophosphate synthase5-hydroxytryptamine receptor 1
go.drugbank.com/bio_entities/BE0004958TargetHumansPlays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism (PubMed:18476671, PubMed:20363322, PubMed:20945968). … G protein-coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:10452531, PubMed:1565658, PubMed:1652050, PubMed:33762731).
Polypeptides: 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1BSynonyms: 5-HT1A, 5-HT-1A5-hydroxytryptamine receptor 3C
go.drugbank.com/bio_entities/BE0009584TargetHumansForms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons
Polypeptides: 5-hydroxytryptamine receptor 3CSynonyms: 5-HT3C, 5-HT3-C5-hydroxytryptamine 3 receptor
go.drugbank.com/bio_entities/BE0009860TargetHumansForms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons … Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons
Polypeptides: 5-hydroxytryptamine receptor 3A, 5-hydroxytryptamine receptor 3BSynonyms: 5-HT-3, 5-HT3A5-hydroxytryptamine receptor 3
go.drugbank.com/bio_entities/BE0010272TargetHumansForms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons … Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons
Polypeptides: 5-hydroxytryptamine receptor 3A, 5-hydroxytryptamine receptor 3BSynonyms: 5-HT-3, 5-HT3AEdoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalTraditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for … In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingProducts: LIXIANA 15 MG, LIXIANA FILM-COATED TABLET 15 MGFusidic acid
go.drugbank.com/drugs/DB02703ApprovedInvestigationalAn antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. … It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.
Mixtures: Fusicutan 20 mg/g + 1 mg/g Creme, FUCICORT 20 MG/G + 1 MG/G KREM, 30 GCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors